Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Uptal Patel
With
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
The Emmes Company, LLC
University of Rochester
OpAns, LLC
Age
2–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Kidney transplant recipient
2. Age 2-17 years, inclusive, at the time of first study dose
3. Estimated GFR (eGFR) ≥30 ml/min/1.73m2, with stable allograft function as indicated by \<20% change in serum creatinine in the previous 30 days
4. Stable immunosuppressive regimen, as indicated by \<10% change in dosage (in mg/kg) in these medications, within the 14 days prior to enrollment
5. Systolic BP \>90th percentile for age, gender, and height, necessitating initiation or addition of an antihypertensive medication
6. For females of child-bearing potential, a negative serum pregnancy test prior to initial dosing and agreement to practice appropriate contraceptive measures, including abstinence, from the time of the initial pregnancy testing through the remainder of the study (30 days after last administration of investigational agents).
You may not be if
1. History of anaphylaxis attributable to lisinopril or other angiotensin-converting enzyme inhibitor (ACEI) agents (e.g.,enalapril, ramipril, quinapril)
2. History of anaphylaxis attributable to iohexol or an iodine hypersensitivity
3. Use of an angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker, or renin antagonist within 30 days prior to enrollment
4. Stage 2 hypertension defined as the \>99th percentile for age, height and gender + 5 mm Hg
5. Blood Potassium value \> 6.0 milliequivalent / liter (mEq/L) (as determined at the screening visit)
6. Previous participation in this study
7. Physician concern that the participant may not adhere to the study protocol, based on prior behavior
